Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazosentan for prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage treated by endovascular coiling
jRCT2080223314Phase 3Completed
- Sponsor
- Idorsia
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in subarachnoid hemorrhage (SAH) and cerebral vasospasm comparing Clazosentan 10 mg/h with Placebo (2 arms). Primary endpoint: Incidence of morbidity/mortality events. Started Sep 2016; status: completed.
02
Drugs
clazosentan
03
Conditions
subarachnoid hemorrhage (SAH)cerebral vasospasm
Beyond the preview
Go deeper on jRCT2080223314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223314.